Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, open-label, controlled study evaluating the use of a sufentanil sublingual tablet (SST) 30 mcg for management of pain of radiofrequency ("RF") microneedling of the face or abdomen

Next Previous
Trial Profile

A prospective, open-label, controlled study evaluating the use of a sufentanil sublingual tablet (SST) 30 mcg for management of pain of radiofrequency ("RF") microneedling of the face or abdomen

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 02 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sufentanil (Primary)
  • Indications Pain
  • Focus Therapeutic Use

Most Recent Events

  • 09 Jan 2024 According to Talphera media release, AcelRx Pharmaceuticals changed its name to Talphera, Inc.
  • 06 Apr 2022 New trial record
  • 31 Mar 2022 Results published in the AcelRx Pharmaceuticals Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top